Wedbush downgraded Iveric bio to Neutral from Outperform with a price target of $40, up from $35, after the company entered into a definitive agreement under which Astellas Pharma will acquire 100% of its outstanding shares for $40 per share in cash for a total equity value of $5.9B.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ISEE:
- Apellis should be bought on selloff from Iveric deal, says Citi
- Iveric bio downgraded to Neutral from Buy at Guggenheim
- Iveric Bio (NASDAQ:ISEE) Sold for $5.9B
- Astellas to acquire Iveric Bio for $40 per share in cash
- Astellas Enters into Definitive Agreement to Acquire Iveric Bio
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue